Sentences with phrase «generic drugmaker akorn»

The Lake Forest - based generic drugmaker alleges in a suit that the German medical equipment giant used a false pretext to walk away from their acquisition agreement.

In an effort to extend the protection, Sanofi obtained a series of patents for other indications, which were challenged by Apotex, a generic drugmaker.

Inexpensive generic drugmaker.

** U.S. generic drugmaker Akorn < AKRX.O > is taking former suitor Fresenius to court after the German healthcare group cancelled their $ 4.75 billion takeover agreement.

It's the first so - called «pay for delay» case brought by the commission in which a drug's original maker agreed not to sell its own «authorized generic» version until well after a generic drugmaker began selling its product.

That guaranteed the generic drugmaker would have no competition, and so could keep prices high, for at least six months.

Mylan NV Executive Chairman Robert Coury was named chairman of the generic drugmaker's board in a move that reduces his role in management of the company and could give Heather Bresch greater responsibilities as chief executive.

(Reuters)- German healthcare conglomerate Fresenius SE & Co KGaA (FREG.DE) is close to acquiring generic drugmaker Akorn Inc (AKRX.O) in an all - cash deal valuing the company at more than $ 4 billion, people familiar with the matter said on Monday.

FRANKFURT (Reuters)- U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $ 4.75 billion takeover agreement.

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $ 4.75 billion takeover agreement.

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $ 4.75 billion (3.4 billion pounds) takeover agreement.

The four companies that challenged the Restasis patents include Teva Pharmaceuticals, the world's largest generic drugmaker, as well as Mylan Pharmaceuticals, Apotex, and Akorn.

Akorn — German drugmaker Fresenius pulled out its $ 4.75 billion deal to buy the U.S. generic drugmaker, saying it had found «material breaches» of Food and Drug Administration data integrity requirements at Akorn.

Akorn shares plummeted Monday after Germany's Fresenius Medical ditched its planned $ 5 billion takeover amid allegations of data misconduct at the Lake Forest, Ill. - based generic drugmaker.

German health - care group Fresenius said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at the U.S. generic drugmaker.

Generic drugmaker Mylan has proposed buying Perrigo for about $ 29 billion in cash and stock in what would be the biggest pharmaceutical deal of the year so far.

• Fresenius SE & Co KGaA (DB: FRE) is close to acquiring Akorn (Nasdaq: AKRX), a Lake Forest, Ill. - based generic drugmaker, in an all - cash deal valuing the company at more than $ 4 billion, according to Reuters.

Indian generic drugmakers currently produce nearly 40 percent of generic drugs and over-the-counter products and 10 percent of finished dosages used in the United States.

Not exact matches

Specialty drugmaker Akorn produces generic and branded prescription drugs in hard - to - make dosages like oral liquids and injectables.

Teva Pharmaceuticals has proposed buying rival Mylan for $ 40 billion in cash and stock, as the Israel - based drugmaker looks to gain dominance among generic pharmaceutical companies.

We cover biopharma companies end - to - end — whether they're small, specialty drugmakers, generics companies or the biggest of Big Pharma — highlighting the accomplishments and acknowledging the defeats that all of them experience in the complicated, competitive pharmaceuticals industry.

This New Jersey - based drugmaker posted a relatively flat year - over-year earnings comparison, which can be attributed to increases in generic competition in several key franchises, which was partially offset by ongoing cost - control initiatives.

The drugmaker's bonds were cut to junk from investment grade by Moody's after its US$ 41 - billion buyout of Allergan Plc's generics business in 2016 left the company with a debt load that outweighed its value in the stock market.